I believe until a milestone is hit ( Cd12 interim, UK EAMS, FDA nod, NASDAQ, and possibly Dr BPs peer reviewed paper) this is going to be our profile. Low volume and trading in a smaller range . The good news I believe is most of the over exuberant share holders and day traders mostly are out and the shorts aren’t having much impact like they did in the Summer because the remaining longs are following the science. We also realize some of this stuff takes time which I believe many before had unrealistic timeframes for the deliverables.